Data as of Jul 25, 2026 · Based on 2,718,867 AI responses across 9,511 prompts · See how Parse measures this
DenovAI Biotechdenovai.com · Low evidenceDenovAI Biotech uses AI and computational molecular biophysics to design proteins de novo—from scratch—creating bespoke biologics, diagnostics, and related molecules. Its platforms enable rapid de novo antibody discovery for high-affinity binders and design of small protein binders tailored to chosen targets, accelerating drug discovery. The company operates within AION Labs with partners such as AstraZeneca, Merck, Pfizer, Teva, AWS, and the Israeli Biotech Fund to advance AI-driven drug discovery and development.
Parse Score